Midi Health BBB and Consumer-Complaint Trends: What the Data Actually Shows

Is Midi Health a Legitimate Telehealth Service?

Midi Health operates as a licensed telehealth platform and is not a fraudulent or scam operation. The company employs state-licensed prescribers, accepts major insurance carriers, and follows telemedicine prescribing laws as outlined by each state medical board. That does not mean patients never encounter problems. Legitimacy and consistent quality are two separate things, and the complaint record shows where gaps exist.

What "Legitimate" Actually Means in Telehealth

The term "legitimate" in U.S. Telehealth has a regulatory meaning. A platform is legitimate when its prescribers hold active, state-appropriate licenses; when prescriptions are transmitted to licensed pharmacies; and when the platform complies with the Ryan Haight Online Pharmacy Consumer Protection Act, which the DEA administers for controlled substances. The FDA also regulates compounded hormone formulations that many menopause platforms dispense, and the agency has published specific guidance on compounded bioidentical hormone therapy (FDA, 2020).

Licensing and Prescriber Credentials

Midi Health's clinical team includes nurse practitioners and physicians. State medical boards, not the company itself, license those practitioners. Patients can verify any prescriber's license through their state medical board directory. The Federation of State Medical Boards maintains a searchable database at fsmb.org, and the National Council of State Boards of Nursing hosts the NursysE-Notify lookup for NP credentials.

Insurance and Cash-Pay Structure

Midi accepts several major commercial insurers. The insured model introduces a claims layer that cash-pay platforms lack, and that layer generates its own complaint category: prior-authorization denials for hormone therapy. The Centers for Medicare and Medicaid Services notes that prior authorization delays are among the top grievance categories filed against managed care organizations (CMS, 2023).

Midi Health BBB Profile: What the Rating Reflects

The Better Business Bureau assigns ratings based on complaint volume, response patterns, time in business, and licensing transparency. As of early 2025, Midi Health does not hold BBB accreditation, which means the company has not paid for and completed the BBB's vetting process. A non-accredited profile is not evidence of fraud; thousands of legitimate businesses carry no BBB accreditation. The BBB's own FAQ clarifies that accreditation "is not a guarantee of a business's reliability or performance" (BBB, 2024).

How BBB Complaint Counts Are Interpreted

BBB complaint volume must be read relative to total patient volume. A platform serving tens of thousands of patients annually that shows 15 to 25 complaints over 36 months has a complaint rate below 0.1%, which is low by consumer-services standards. The FTC received 2.6 million fraud reports in 2023 alone across all industry sectors (FTC Consumer Sentinel Network, 2024). Telehealth-specific complaints are a subset of that figure, but raw counts without denominators tell an incomplete story.

Recurring Complaint Themes

Three complaint themes appear with consistency in consumer-facing platforms when patients discuss Midi Health publicly:

1. Billing and insurance disputes. Patients report unexpected out-of-pocket charges after receiving assurances that their insurer covers menopause services. This pattern is not unique to Midi; it reflects widespread insurer ambiguity around "women's preventive care" CPT coding for hormone consultations.

2. Prescription turnaround delays. Patients waiting for compounded progesterone or estradiol formulations report turnarounds of 10 to 21 days. FDA-registered compounding pharmacies must complete quality-release testing before shipping, which adds time compared with a retail pharmacy dispensing an FDA-approved product (FDA, 2022).

3. Care-coordination gaps. Some patients report difficulty reaching their assigned provider for follow-up questions after initial prescribing. Asynchronous telehealth models depend on messaging systems, and response-time standards vary by platform.

The Clinical Context: Why Menopause Telehealth Complaints Have a Unique Profile

Menopause care sits at the intersection of a historically undertreated condition and a newly crowded telehealth market. The 2022 NAMS Position Statement on menopausal hormone therapy states that "for most women younger than 60 years or within 10 years of menopause onset, the benefits of MHT for bothersome vasomotor symptoms outweigh the risks" (NAMS, 2022). That endorsement drove a significant increase in demand for hormone prescribing services, which in turn drove new platforms into the market quickly.

Demand Surge and Quality Pressure

The number of U.S. Women aged 40 to 64 who report moderate-to-severe vasomotor symptoms is estimated at 6,000 to 7,000 per 100,000 in that age cohort, based on data from the Study of Women's Health Across the Nation (SWAN, NEJM 2021). That is a large addressable population. Platforms scaling to meet that demand sometimes outpace their operational infrastructure, which is when billing and care-coordination complaints tend to rise.

Compounded vs. FDA-Approved Hormone Products

A clinically relevant complaint subcategory involves patients who expected FDA-approved hormone therapy but received a compounded formulation instead. The FDA distinguishes clearly between the two: approved products (such as Vivelle-Dot 0.05 mg/24h estradiol patch, Climara, and oral progesterone Prometrium 100 mg) have demonstrated safety and efficacy data, while compounded hormones are not FDA-approved and have not undergone the same pre-market review (FDA, 2020). Patients who receive compounded estriol-progesterone creams without understanding that distinction may feel misled, even when the prescribing is clinically defensible.

The NAMS Position on Compounded Hormones

The North American Menopause Society has been direct on this point. Its 2022 position statement notes that "custom-compounded hormones are not recommended for most women because they carry more risks than FDA-approved hormone therapies." That statement provides patients with a benchmark against which to evaluate any telehealth platform's prescribing defaults (NAMS, 2022).

Regulatory Oversight Applicable to Midi Health

No single federal agency regulates telehealth platforms end to end. Oversight is distributed across multiple bodies, each with a defined lane.

FDA Jurisdiction

The FDA oversees drug products, including compounded hormones dispensed by outsourcing facilities. If a platform's pharmacy partner is a 503B outsourcing facility, it is subject to FDA inspection and current good manufacturing practice standards. The FDA's registered outsourcing facility list is publicly searchable (FDA Outsourcing Facilities List, 2024).

FTC Advertising Standards

The FTC enforces Section 5 of the FTC Act against deceptive health claims in telehealth advertising. Platforms that advertise "FDA-approved bioidentical hormones" when they dispense compounded products risk FTC action. The agency settled with multiple compounding pharmacies between 2020 and 2024 for misrepresenting regulatory status (FTC, 2024).

State Medical Board Authority

State boards hold ultimate authority over prescriber conduct within their jurisdiction. A patient who believes a Midi Health prescriber provided negligent care can file a complaint with the board in the state where the prescriber is licensed. State board complaint data is public record and is a more granular signal of clinical quality than BBB ratings.

DEA and the Ryan Haight Act

For any controlled substance (some testosterone formulations, certain sleep medications), Midi Health prescribers must comply with the Ryan Haight Online Pharmacy Consumer Protection Act. The DEA's temporary COVID-era telemedicine flexibilities for Schedule III to V substances were extended through December 31, 2025, per the DEA's March 2024 interim final rule (DEA, 2024). That extension affects whether Midi can prescribe low-dose testosterone for women without requiring an in-person visit first.

How Midi Health Compares to Telehealth Quality Benchmarks

Evaluating a telehealth platform against general telehealth quality benchmarks requires a structured framework. The table below applies four dimensions drawn from the National Committee for Quality Assurance's telehealth standards and the URAC Health Website Accreditation criteria.

| Dimension | NCQA/URAC Benchmark | Midi Health Signal | |---|---|---| | Prescriber licensure transparency | License numbers publicly accessible or provided on request | Reported as available on request; not proactively displayed | | Complaint response time | Acknowledge within 5 business days | BBB profile shows mixed response patterns | | Informed consent for compounded products | Written disclosure of non-FDA-approved status | Patient reports vary; some indicate this was not emphasized | | Follow-up protocol | Documented follow-up within 90 days of new Rx | Not publicly standardized |

The NCQA has noted that telehealth-specific quality measures remain "less mature" than measures for in-person care, with formal measure sets still under development as of 2023 (NCQA, 2023).

What Patients Report Doing Right at Midi Health

Complaints receive disproportionate attention in any review. Patient feedback on platforms including Trustpilot, Reddit's r/Menopause community, and employer-benefit forums includes consistent positive notes on:

• Appointment availability within 48 to 72 hours, compared to the national average of 26 days to see an OB-GYN for a new-patient appointment, per a 2022 Merritt Hawkins survey.
• Provider familiarity with menopause-specific symptom clusters, including genitourinary syndrome of menopause (GSM), which a 2021 ACOG Practice Bulletin describes as affecting up to 50% of postmenopausal women (ACOG Practice Bulletin 141, reaffirmed 2021).
• Insurance billing handled by the platform rather than the patient, reducing administrative burden.

These positives do not cancel out the complaint patterns described above, but they provide necessary context for an accurate picture.

Red Flags to Watch for Before and During Enrollment

Patients considering Midi Health or any menopause telehealth platform should watch for these specific signals:

Before the First Appointment

Check that the assigned prescriber holds an active license in your state. Request the prescriber's NPI number and verify it at npiregistry.cms.hhs.gov. A platform that cannot or will not provide that number within 24 hours of a request is a compliance concern.

At the Prescribing Appointment

Ask whether the proposed treatment uses an FDA-approved product or a compounded formulation. If compounded, ask which pharmacy will fill the prescription and confirm that pharmacy is either a state-licensed retail compounding pharmacy or an FDA-registered 503B outsourcing facility. Compounded products are not inherently unsafe, but patients deserve to understand what they are receiving.

After Prescribing

Request a written summary of the treatment plan, including the diagnosis code (ICD-10), the drug name, dose, and the follow-up schedule. The American College of Obstetricians and Gynecologists recommends reassessing menopausal hormone therapy at least annually, and that annual-review protocol should be built into any telehealth platform's workflow (ACOG, 2022).

Filing a Complaint: Step-by-Step Options

If you have a dispute with Midi Health, these are the relevant channels in order of likely effectiveness:

1. Internal grievance process. Contact Midi Health's patient support in writing. Keep records. Most billing disputes resolve at this stage.

2. State insurance commissioner. If the dispute involves insurance billing, file with your state's insurance commissioner. Each state maintains an online complaint portal. The National Association of Insurance Commissioners maintains a directory at naic.org.

3. State medical board. If the complaint involves clinical conduct, contact the board where your prescriber is licensed. Board complaint forms are public and free to file.

4. FTC Report. File at reportfraud.ftc.gov for deceptive advertising claims. The FTC uses aggregated complaint data to identify enforcement targets, so individual reports contribute to systemic action even if no individual case is opened.

5. BBB complaint. File at bbb.org/file-a-complaint. BBB complaints generate a formal response request from the business within 14 days and become part of the public profile.

6. CMS Medicare/Medicaid complaints. If you are enrolled in a Medicare Advantage or Medicaid managed care plan and believe a prior authorization was improperly denied, file with CMS at medicare.gov/claims-appeals.

Clinical Standards That Should Govern Any Menopause Telehealth Visit

Regardless of platform, the clinical minimum for a menopause telehealth consultation should align with published guidelines. The Endocrine Society's 2015 Clinical Practice Guideline on menopause recommends a symptom assessment, blood pressure measurement (or patient-reported measurement), and discussion of cardiovascular and breast cancer risk before initiating systemic hormone therapy (Endocrine Society, 2015). A platform that skips risk stratification and moves directly to prescribing is operating below guideline standard.

The NAMS 2022 Position Statement recommends using the lowest effective dose for the shortest duration consistent with treatment goals, and reassessing annually (NAMS, 2022). Patients should ask any platform whether their prescribing protocol reflects that guidance.